雌二醇对围绝经期快感缺失与精神病性症状影响研究(PEEPs):神经与分子机制临床试验方案
PEEPs是一项机制性临床试验,计划招募100名44-55岁未用药的围绝经期晚期女性,随机接受雌二醇或安慰剂治疗3周,评估快感缺失(SHAPS)和精神病性症状(BPRS精神病性亚量表)及中脑边缘奖赏系统功能(fMRI奖赏相关激活和PET纹状体多巴胺结合),旨在识别围绝经期起病的快感缺失和精神病性症状与神经分子标记的关系,并确定雌二醇治疗诱导的奖赏反应变化与症状缓解的关联程度。
要点
- 围绝经期过渡期超过10%的女性伴随精神症状,常见抑郁心境和快感缺失,较少见精神病性症状。
- 雌二醇治疗可减轻部分围绝经期女性的快感缺失和精神病性症状。
- 本试验将雌二醇或安慰剂治疗3周,评估奖赏相关fMRI激活和PET纹状体多巴胺结合。
核心结论
- 本临床试验将首次描述雌二醇治疗改善围绝经期过渡期快感缺失和精神病性症状的神经与分子机制,为未来生物标志物研究奠定基础,以预测易感性和预后并开发针对性治疗。
- 该试验将增进对以快感缺失、精神病性症状和奖赏系统功能障碍为特征的一系列疾病的理解。
研究设计与样本
- PEEPs是一项机制性临床试验,计划招募100名44-55岁未用药的围绝经期晚期女性,在轻度至高度快感缺失和无至中度精神病性症状范围内取样。
- 患者随机接受雌二醇或安慰剂治疗3周。
- 试验注册号:ClinicalTrials.gov NCT05282277。
主要发现
- 将检查治疗前SHAPS/BPRS评分与奖赏相关纹状体多巴胺结合/BOLD激活之间的关联。
- 将使用纵向混合模型估计症状和神经分子轨迹随雌二醇与安慰剂治疗的变化。
- 将估计奖赏相关纹状体多巴胺结合和BOLD激活的变化如何预测雌二醇治疗反应中症状轨迹的变异性。
关键数值与推荐
- 临床结局指标包括快感缺失症状(采用Snaith-Hamilton快感量表SHAPS测量)和精神病性症状(采用简明精神病评定量表BPRS精神病性亚量表测量)。
- 神经标记包括奖赏相关fMRI激活和PET衍生的纹状体多巴胺结合测量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The perimenopausal transition is accompanied by psychiatric symptoms in over 10% of women. Symptoms commonly include depressed mood and anhedonia and less commonly include psychosis. Psychiatric symptoms have been linked to the depletion and/or variability of circulating estradiol, and estradiol treatment reduces perimenopausal anhedonia and psychosis in some women. Estrogen fluctuations may disrupt function in the mesolimbic reward system in some women, leading to psychiatric symptoms like anhedonia or psychosis. The Perimenopausal Effects of Estradiol on Anhedonia and Psychosis Study (PEEPs) is a mechanistic clinical trial that aims to (1) identify relationships between perimenopausal-onset anhedonia and psychosis and neuromolecular markers of mesolimbic reward responses and (2) determine the extent to which estradiol treatment-induced changes in mesolimbic reward responses are associated with alleviation of perimenopausal onset anhedonia or psychosis. METHODS: This study will recruit 100 unmedicated women ages 44-55 in the late-stage perimenopausal transition, sampling across the range of mild-to-high anhedonia and absent-to-moderate psychosis symptoms. Patients will be randomized to receive either estradiol or placebo treatment for 3 weeks. Clinical outcome measures will include symptoms of anhedonia (measured with Snaith-Hamilton Pleasure Scale; SHAPS) and psychosis (measured with Brief Psychiatric Rating Scale; BPRS psychosis subscale) as well as neural markers of mesolimbic reward system functioning, including reward-related fMRI activation and PET-derived measure of striatal dopamine binding. Pre-treatment associations between (1) SHAPS/BPRS scores and (2) reward-related striatal dopamine binding/BOLD activation will be examined. Furthermore, longitudinal mixed models will be used to estimate (1) symptom and neuromolecular trajectories as a function of estradiol vs. placebo treatment and (2) how changes in reward-related striatal dopamine binding and BOLD activation predict variability in symptom trajectories in response to estradiol treatment. DISCUSSION: This clinical trial will be the first to characterize neural and molecular mechanisms by which estradiol treatment ameliorates anhedonia and psychosis symptoms during the perimenopausal transition, thus laying the groundwork for future biomarker research to predict susceptibility and prognosis and develop targeted treatments for perimenopausal psychiatric symptoms. Furthermore, in alignment with the National Institute for Mental Health Research Domain Criteria initiative, this trial will improve our understanding of a range of disorders characterized by anhedonia, psychosis, and reward system dysfunction. TRIAL REGISTRATION: ClinicalTrials.gov NCT05282277.
引用
- Walsh MJM, Gibson K, Hynd M, et al. Perimenopausal Effects of Estradiol on Anhedonia and Psychosis Study (PEEPs): study protocol for a neural and molecular mechanistic clinical trial. Trials. 2023. PMID: 36855177. doi:10.1186/s13063-023-07166-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。